Floatz logo

ds-8201a

Neoplasm Metastasis

Daiichi Sankyo Co., Ltd.antibody_drug_conjugatePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

171 Active assets in the Neoplasm Metastasis cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Eloxatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Ipilimumab
7 Hills Pharma, LLC
Phase 3BB

View all 50 →

Same molecule, other indications

ds-8201a is also rated in:

breast neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
Residual Invasive Breast CancerDormant
B
Indicative ·
60 / 100
View asset →
HER2 positive breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →